Articles tagged with: Vorinostat
Treatment strategies that combine Revlimid with newer types of anti-tumor agents may be effective for relapsed and refractory multiple myeloma, according to myeloma experts who reviewed results from studies of these new combinations.
Refractory and relapsed multiple myeloma is notoriously difficult to treat. For every remission period that is achieved, relapse typically arises sooner and with greater resistance to previously used therapies. These patients have limited options for therapy.
In examining trials that tested new therapies in combination with Revlimid (lenalidomide), the authors of the review hoped to find …
The National Comprehensive Cancer Network (NCCN) has updated its guidelines for the treatment of multiple myeloma, and the new guidelines will be interpreted by many as a vote of confidence for Revlimid maintenance therapy.
The NCCN guidelines are followed closely by physicians and by many U.S. health insurance companies, which frequently use them when making reimbursement decisions about different cancer treatments.
The guidelines are comprised of recommendations based on the results of recent clinical trials and ongoing scientific research. A panel of specialists within the myeloma field is responsible for …
Four clinical trials presented at the American Society of Hematology (ASH) 2011 annual meeting in San Diego last month suggest that Zolinza, in combination with a number of approved myeloma drugs, may be a treatment option for relapsed and treatment-resistant multiple myeloma patients.
However, results of a key Phase 3 trial involving the drug were disappointing, and they call into question whether the drug will receive formal FDA approval as a treatment for myeloma.
Zolinza (vorinostat), which is marketed by the U.S. pharmaceutical company Merck (NYSE: MRK), is an oral …
It has been ten days since the 2011 annual meeting of the American Society of Hematology (ASH) came to a close.
In this and The Beacon’s next article about the meeting, however, the perspective changes a bit.
The focus shifts to the bigger picture — to questions like: “What was the impact of the …
As the third day of the 2011 American Society of Hematology (ASH) annual meeting came to an end, attendees could look back on an agenda that featured presentations about a wide range of potential new myeloma therapies.
The afternoon myeloma sessions were focused, in fact, on potential new therapies.
This update covers the afternoon’s presentations about four other potential new myeloma therapies — …